Baxter (BAX) Tops Q2 EPS by 5c
Get Alerts BAX Hot Sheet
Revenue Growth %: -2.7%
Financial Fact:
Marketing and administrative expenses: 726M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Baxter (NYSE: BAX) reported Q2 EPS of $1.00, ex-items, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.77 billion.
Baxter sees Q3 2015 EPS of $0.29-$0.31, versus the consensus of $0.27.
''The spin-off of Baxalta was a historic event for the company, and we are excited to embark on this new chapter for Baxter with a newfound focus and vision that furthers our mission to help save and sustain lives,'' said Robert L. Parkinson, Jr., chairman and chief executive officer. ''As the new Baxter evolves, we are intensely focused on accelerating profitable growth and expanding margins through disciplined portfolio management, implementation of cost reduction initiatives and the near-term launches of innovative new products. These efforts will drive meaningful value, both in the near and long terms, for our shareholders, partners, employees, and the patients and healthcare providers we serve.''
For earnings history and earnings-related data on Baxter (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!